Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 8 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Mindset Pharma Inc. is managing 11 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 8 distinct art units. The prosecution involves 10 distinct examiners, meaning that almost every pending action is being reviewed by a different person.
TRAN, ERIC is the busiest examiner for this portfolio, with 2 pending office actions. These 2 actions are part of the 11 total pending actions. Navigating 8 distinct art units with 10 distinct examiners requires attention to various examination standards within the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §102 only | 1 (9%) |
| §112 only | 4 (36%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 2 | 69.8% | +19.4% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279290 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | AULAKH, CHARANJIT | 5d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | LEE, CHIHYI NMN | 26d overdue |
| 19413522 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | — |
| 18683854 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MAHLUM, JONATHAN DAVIS | — |
| 18683846 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | BELL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17387883 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MCDOWELL, BRIAN E | 89d overdue |
| 19189953 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | 44d overdue |
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | LEE, CHIHYI NMN | 26d overdue |
| 19568483 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 19413522 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | — |
| 18683854 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MAHLUM, JONATHAN DAVIS | — |
| 18683846 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | BELL, SARA ELIZABETH | — |
| 18563898 | HALLUCINOGEN-FATTY ACID COMBINATION | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1629 | 3 |
| 1625 | 2 |
| 1622 | 1 |
| 1612 | 1 |
| 1623 | 1 |
| 1621 | 1 |
| 1628 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19568483 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Final Rejection | — | Pending | Mar 16, 2026 |
| 19413522 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | 1629 | §102§112 | Non-Final OA | — | Pending | Dec 09, 2025 |
| 19189953 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TRAN, ERIC | 1629 | §103 | Non-Final OA | 44d overdue | Pending | Apr 25, 2025 |
| 18683854 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MAHLUM, JONATHAN DAVIS | 1625 | §102§103§112Other | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18683842 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | WEDDINGTON, KEVIN E | 1629 | §112Other | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18683846 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | BELL, SARA ELIZABETH | 1625 | §102§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18563898 | HALLUCINOGEN-FATTY ACID COMBINATION | RONEY, CELESTE A | 1612 | §112 | Non-Final OA | — | Pending | Nov 23, 2023 |
| 18279293 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Final Rejection | 48d | Pending | Aug 29, 2023 |
| 18279290 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | 5d | Pending | Aug 29, 2023 |
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | LEE, CHIHYI NMN | 1628 | §103§112 | Final Rejection | 26d overdue | Pending | Jun 05, 2023 |
| 17387883 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MCDOWELL, BRIAN E | 1624 | §102 | Final Rejection | 89d overdue | Pending | Jul 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMindset Pharma Inc. has 11 pending office actions as of October 2026, spread across 8 art units and 10 examiners.
Eric Tran has the most, with 2 of Mindset Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
